Nayyereh Saadati; Mandana khodashahi; Zahra Rezaieyazdi; Maryam Sahebari; Zeinab Saremi; Saeed Mohammadian Haftcheshmeh; Houshang Rafatpanah; Maryam Salehi
Abstract
Background: Rheumatoid arthritis (RA) is described as a systemic and chronic autoimmune disease characterized by inflammatory polyarthritis. Lymphocyte-activation gene 3 (LAG3) is a membrane glycoprotein expressed on activated, exhausted, and regulatory T cells. LAG3 plays a major role in the function ...
Read More
Background: Rheumatoid arthritis (RA) is described as a systemic and chronic autoimmune disease characterized by inflammatory polyarthritis. Lymphocyte-activation gene 3 (LAG3) is a membrane glycoprotein expressed on activated, exhausted, and regulatory T cells. LAG3 plays a major role in the function of Treg cells. LAG3 also has a soluble form (sLAG3) with a controversial role. Objective: To evaluate the serum level of sLAG3 in rheumatoid arthritis patients in comparison with healthy subjects and assess its association with the disease activity. Methods: This cross-sectional study was performed on 105 patients with RA referred to Ghaem hospital of Mashhad, Iran. We divided the participants into four groups: 1) 35 untreated patients with newly diagnosed RA, 2) 35 active RA patients, 3) 35 patients in the remission phase of the disease, and 4) 35 healthy individuals matched in terms of age and sex. After completing the interview and questionnaire, the sLAG3 was evaluated by commercial ELISA. Results: The serum level of sLAG3 significantly increased in RA patients (76.78 ng/ml) as compared with the healthy participants (51.67, p=0.002). However, there was no significant difference between RA patients in the remission phase of the disease (114.11 ng/ml) and those with moderate to high disease activity (63.06 ng/ml, p=0.076). Conclusion: This study provided insights into the role of sLAG3 in the immunopathogenesis of RA disease, but further investigations are also warranted.
Reza Feyzi; Mohammad Hossein Boskabady; Seyedeh Masoumeh Seyed hosseini Tamijani; Houshang Rafatpanah; Seyed Abdolrahim Rezaei
Volume 13, Issue 4 , December 2016, , Pages 263-273
Abstract
Background: Several biological and medical benefits of Saffron, Crocus sativus
(Iridaceae), have been demonstrated. However, mechanisms of actions for purified
constituents are greatly unknown. Objective: To examine the effects of Safranal, a main
constituent of Saffron stigma, on cell viability and ...
Read More
Background: Several biological and medical benefits of Saffron, Crocus sativus
(Iridaceae), have been demonstrated. However, mechanisms of actions for purified
constituents are greatly unknown. Objective: To examine the effects of Safranal, a main
constituent of Saffron stigma, on cell viability and cytokine profile of peripheral blood
mononuclear cells (PBMC) were examined. Methods: Effects of Safranal at 0.1, 0.5
and 1 mM concentrations were evaluated on cell viability and production of interleukin
4 (IL-4), IL-10 and interferon-γ (IFN-γ) from non-stimulated and phytohemagglutinin
(PHA) stimulated PBMCs, compared to 0.1 mM dexamethasone and saline. Results: In
stimulated cells, different concentrations of Safranal caused significant decrease of
lymphocytes viability (p<0.001 for all concentrations). All concentrations of Safranal
inhibited IFN-γ and IL-10 secretion in stimulated cells (p<0.01). In addition, high
concentration of Safranal significantly decreased cell viability of non-stimulated
PBMCs (p<0.001). The effect of 1 mM Safranal on IL-4 secretion was less than
dexamethasone (p<0.05). Safranal showed a stimulatory effect on IFN-γ secretion in
non-stimulated cells. The IFN-γ/IL-4 ratio at the presence of two higher Safranal
concentrations both in non-stimulated and stimulated cells were significantly higher
than those of control and PHA stimulated groups, respectively (p<0.05). Conclusion:
The IFN-γ/IL-4 ratio increases in the presence of Safranal which indicates an effect on
Th1/Th2 balance. Therefore, Safranal may have therapeutic effects in inflammatory
diseases associated with Th1/Th2 imbalance.
